psy 627 Exam 3 Questions With Correct
Answers
What |drug |class |or |combination |of |drugs |may |be |effective |for |patients |with |treatment-
resistant |depression |(have |not |responded |to |other |antidepressants)?
SSRI |with |a |5-HT2A |antagonist/D2 |antagonist |with |5-HT1A |partial |agonism
what |5-HT1A |agonist |is |approved |for |reducing |suicide?
clozapine
What |is |appropriate |augmenting |drugs |for |treating |depression?
stimulants |(modafinil |or |ADHD |drugs)
Do |the |benefits |of |pharmacotherapy |for |a |woman |suffering |from |major |depression |during |
pregnancy |or |in |the |postpartum |period |generally |outweigh |the |risks |to |mother |and |infant, |
especially |if |the |mother |has |severe |symptoms |or |is |in |the |postpartum |period?
the |benefits |of |SSRIs |strongly |outweigh |the |risks
, Should |SSRIs |always |be |avoided |during |pregnancy |due |to |major |neonatal |malformations?
No. |No |significant |increased |risk |when |confounds |were |controlled
Is |it |possible |to |predict |if |an |individual |has |an |increased |risk |of |postpartum |depression, |based |
on |the |number |of |previous |depressive |episodes?
yes.
Highest |risk: |4-6 |weeks |postpartum
No |prior |depression |8-10%
History |of |depression |25%
History |of |postpartum |depression |67%
If |she |takes |an |antidepressant |7%
What |drug |has |been |specifically |FDA-approved |to |treat |postpartum |depression?
brexanalone |(Zulresso)
Generally, |which |mechanism |of |action |is |least |likely |to |increase |general |activation |or |arousal?
Answers
What |drug |class |or |combination |of |drugs |may |be |effective |for |patients |with |treatment-
resistant |depression |(have |not |responded |to |other |antidepressants)?
SSRI |with |a |5-HT2A |antagonist/D2 |antagonist |with |5-HT1A |partial |agonism
what |5-HT1A |agonist |is |approved |for |reducing |suicide?
clozapine
What |is |appropriate |augmenting |drugs |for |treating |depression?
stimulants |(modafinil |or |ADHD |drugs)
Do |the |benefits |of |pharmacotherapy |for |a |woman |suffering |from |major |depression |during |
pregnancy |or |in |the |postpartum |period |generally |outweigh |the |risks |to |mother |and |infant, |
especially |if |the |mother |has |severe |symptoms |or |is |in |the |postpartum |period?
the |benefits |of |SSRIs |strongly |outweigh |the |risks
, Should |SSRIs |always |be |avoided |during |pregnancy |due |to |major |neonatal |malformations?
No. |No |significant |increased |risk |when |confounds |were |controlled
Is |it |possible |to |predict |if |an |individual |has |an |increased |risk |of |postpartum |depression, |based |
on |the |number |of |previous |depressive |episodes?
yes.
Highest |risk: |4-6 |weeks |postpartum
No |prior |depression |8-10%
History |of |depression |25%
History |of |postpartum |depression |67%
If |she |takes |an |antidepressant |7%
What |drug |has |been |specifically |FDA-approved |to |treat |postpartum |depression?
brexanalone |(Zulresso)
Generally, |which |mechanism |of |action |is |least |likely |to |increase |general |activation |or |arousal?
